Header

GYN: Ovarian, Fallopian, Peritoneal Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 24 Trial

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 3

Protocol Number: 14-050

Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovari...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 2 / 3

Protocol Number: 16-715

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer

Phase: 2

Protocol Number: 15-547

A Phase II Study Of Nivolumab/ Bevacizumab

This research study is evaluating two drugs called Nivolumab and Bevacizumab as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 2

Protocol Number: 16-263

The Women Choosing Surgical Prevention (WISP) Trial

The goal of this clinical research study is to compare the changes in female sexual function between patients having interval salpingectomy with delayed oophorectomy (ISDO) with those having risk-r...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 2

Protocol Number: 16-389

Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, PLD or Pembrolizumab in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer

This is a phase 1b study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of four regimens: I...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number: 15-505

Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

This phase I trial studies the side effects and best dose of olaparib and Hsp90 inhibitor AT13387 when given together in treating patients with solid tumors that have spread to other places in the ...

Diagnosis: Breast: Metastatic, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number: 17-715

The HOPE Trial:Helping Our Patients Excel

This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with Fitbit devices. The HOPE app was designed to learn about improving qu...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Cervical Cancer

Phase:

Protocol Number: 16-477

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a p...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Breast: Metastatic

Phase:

Protocol Number: 17-285

Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer

This research study will test whether using wearable fitness trackers with or without a social incentive, delivered through a game-based mobile health intervention, increases physical activity and ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 17-361

Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

This is a Phase 1a/1b study of SC-003 in patients with platinum-resistant/refractory ovarian cancer. SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 17-240

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with ovarian cancer and their caregivers after a hospitalization.

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 17-475

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer....

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Vulvar Cancer, Radiation Oncology, GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Cervical Cancer

Phase:

Protocol Number: 17-382

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

First-in-human, Phase 1b safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every three weeks. Patients with tumor types likely to express NaPi2...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Thyroid Cancer, GYN: Endometrial/Uterine Cancer, Solid Tumor/Phase I, Lung Cancer

Phase:

Protocol Number: 17-621

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204)

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovaria...

Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 17-499

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 17-511

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 18-077

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), trip...

Diagnosis: Breast: Early Stage Disease, GYN: Ovarian, Fallopian, Peritoneal Cancer, Lung Cancer, Solid Tumor/Phase I, Prostate Cancer

Phase:

Protocol Number: 17-687

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

This research study is studying a combination of two drug interventions called rosuvastatin and enoxaparin as a possible preventative measure against developing venous blood clots (such deep vein t...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 18-067

Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer

This study is a phase 2, multi-cohort study, which will assess the safety and efficacy of new treatment combinations in patients with recurrent ovarian cancer.

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 18-303

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer

The primary objectives of the Dose Escalation Phase are to assess the safety and pharmacokinetics (PK) in order to determine a maximally tolerated dose (MTD) or recommended phase 2 dose (RP2D) of R...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 18-227

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Primary Objectives: - Phase1: To characterize the safety and tolerability of isatuximab in combination with atezolizumab in participants with unresectable hepatocellular carcinoma (HCC), platinum-r...

Diagnosis: Brain/Neuro Cancer: Recurrent Glioblastoma, Head and Neck Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer, Liver Cancer

Phase:

Protocol Number: 18-332

Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRPĀ®

This study is to be performed as an open label, multicenter, single arm study of 2X-121 to evaluate anti-tumor efficacy of 2X-121 as single agent therapy in a 28-days cycle in advanced ovarian canc...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 18-633

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back. Adavosertib and ol...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase:

Protocol Number: 19-059

'